FDA Awards Priority Voucher for Copper Drug Treating Kids' Disease
Published Date: 2/27/2026
Notice
Summary
The FDA just gave Sentynl Therapeutics a special priority review voucher for their new rare pediatric disease drug, ZYCUBO, which treats Menkes disease in kids. This voucher speeds up future FDA reviews, helping get important medicines to patients faster. The approval happened on January 12, 2026, and this voucher could also be sold or used to speed up other drug reviews, potentially saving time and money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ZYCUBO Approved for Menkes Disease
If you have a child with Menkes disease, the FDA approved ZYCUBO (copper histidinate) for treatment on January 12, 2026. This approval means pediatric patients with Menkes disease have an FDA‑approved treatment option.
Priority Review Voucher Can Speed Reviews
The FDA issued a Rare Pediatric Disease Priority Review Voucher tied to ZYCUBO; the voucher can be used or sold to speed the FDA review of another drug. If you or someone you care for needs a rare‑disease medicine, using or selling this voucher can help get other important drugs to patients faster and may save time and money.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-03924 — Certain Beverage Brewing Products and Components Thereof; Notice of Institution of Investigation
Adrian Rivera Maynez Enterprises is asking the U.S. International Trade Commission to investigate certain beverage brewing products that might be breaking their patents. If the investigation agrees, some products could be blocked from being sold or imported into the U.S., which could shake up the market soon. This means companies selling these products should watch out for possible legal changes and restrictions starting in 2026.
Next: 2026-03926 — Commercial Driver's License Standards: Application for Exemption Renewal; Wilson Logistics
Wilson Logistics got the green light to keep their special exemption that lets a learner driver train without a fully licensed driver sitting right next to them—once the learner has passed their skills test. This renewal runs from February 24, 2026, to February 24, 2031, and keeps safety standards strong while giving Wilson Logistics some training flexibility. Drivers, trainers, and the company all benefit from this smart, safety-approved update with no extra costs.